BR9508187A - Produtos e composição farmacêutica - Google Patents
Produtos e composição farmacêuticaInfo
- Publication number
- BR9508187A BR9508187A BR9508187A BR9508187A BR9508187A BR 9508187 A BR9508187 A BR 9508187A BR 9508187 A BR9508187 A BR 9508187A BR 9508187 A BR9508187 A BR 9508187A BR 9508187 A BR9508187 A BR 9508187A
- Authority
- BR
- Brazil
- Prior art keywords
- radical
- alkyl
- optionally substituted
- general formula
- carbon atoms
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9407116A FR2721021B1 (fr) | 1994-06-10 | 1994-06-10 | Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent. |
| FR9412338A FR2725717B1 (fr) | 1994-10-17 | 1994-10-17 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/FR1995/000739 WO1995034535A1 (fr) | 1994-06-10 | 1995-06-07 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9508187A true BR9508187A (pt) | 1997-08-12 |
Family
ID=26231226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9508187A BR9508187A (pt) | 1994-06-10 | 1995-06-07 | Produtos e composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0764149B1 (pt) |
| JP (1) | JPH10501259A (pt) |
| CN (1) | CN1150419A (pt) |
| AT (1) | ATE175958T1 (pt) |
| AU (1) | AU2742195A (pt) |
| BR (1) | BR9508187A (pt) |
| CA (1) | CA2192389A1 (pt) |
| CZ (1) | CZ361996A3 (pt) |
| DE (1) | DE69507476D1 (pt) |
| FI (1) | FI964920A7 (pt) |
| NO (1) | NO965160L (pt) |
| PL (1) | PL317580A1 (pt) |
| SK (1) | SK158196A3 (pt) |
| TW (1) | TW365602B (pt) |
| WO (1) | WO1995034535A1 (pt) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6678398A (en) | 1997-02-27 | 1998-09-18 | Ana Maria Garcia | Inhibitors of isoprenyl transferase |
| GB2323842A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv | Pyridine derivatives |
| GB2323841A (en) * | 1997-04-04 | 1998-10-07 | Ferring Bv Group Holdings | Pyridine derivatives with anti-tumor and anti-inflammatory activity |
| US6071547A (en) * | 1998-10-08 | 2000-06-06 | Superior Nutrition Corporation | Textured dry mix instant nutritional drink |
| US6486202B1 (en) | 2001-04-13 | 2002-11-26 | Eisai Company, Limited | Inhibitors of isoprenyl transferase |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2008013427A (es) | 2006-04-19 | 2008-11-04 | Novartis Ag | Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r. |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| MX2009007200A (es) | 2007-01-10 | 2009-07-15 | Angeletti P Ist Richerche Bio | Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp). |
| US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
| US8293769B2 (en) | 2007-05-21 | 2012-10-23 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010144909A1 (en) | 2009-06-12 | 2010-12-16 | Novartis Ag | Fused heterocyclic compounds and their uses |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| WO2011115725A2 (en) | 2010-03-16 | 2011-09-22 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RU2660349C2 (ru) | 2012-11-28 | 2018-07-05 | Мерк Шарп И Доум Корп. | Композиции и способы для лечения злокачественной опухоли |
| BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| CN105849087A (zh) | 2013-12-27 | 2016-08-10 | 诺华丝国际股份有限公司 | 乙氧基化表面活性剂 |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| HK1245260A1 (zh) | 2014-12-23 | 2018-08-24 | Dana-Farber Cancer Institute, Inc. | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN109071425B (zh) * | 2016-03-23 | 2021-01-15 | 陈裕仁 | 法尼基转移酶抑制剂及其用途 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| MA53287A (fr) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme | Inhibiteurs de prmt5 |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3124422A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| CN120917311A (zh) | 2023-03-02 | 2025-11-07 | 卡西蒙生物技术有限责任公司 | 用于诊断癌症和/或急性炎性疾病的手段和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2044333A1 (en) * | 1990-06-12 | 1991-12-13 | Jackson B. Gibbs | Chemotherapeutic agents |
| US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5504212A (en) * | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-06-07 AT AT95922573T patent/ATE175958T1/de not_active IP Right Cessation
- 1995-06-07 WO PCT/FR1995/000739 patent/WO1995034535A1/fr not_active Ceased
- 1995-06-07 SK SK1581-96A patent/SK158196A3/sk unknown
- 1995-06-07 CA CA002192389A patent/CA2192389A1/fr not_active Abandoned
- 1995-06-07 CZ CZ963619A patent/CZ361996A3/cs unknown
- 1995-06-07 DE DE69507476T patent/DE69507476D1/de not_active Expired - Lifetime
- 1995-06-07 CN CN95193511A patent/CN1150419A/zh active Pending
- 1995-06-07 AU AU27421/95A patent/AU2742195A/en not_active Abandoned
- 1995-06-07 JP JP8501714A patent/JPH10501259A/ja active Pending
- 1995-06-07 PL PL95317580A patent/PL317580A1/xx unknown
- 1995-06-07 TW TW084105739A patent/TW365602B/zh active
- 1995-06-07 BR BR9508187A patent/BR9508187A/pt not_active Application Discontinuation
- 1995-06-07 EP EP95922573A patent/EP0764149B1/fr not_active Expired - Lifetime
-
1996
- 1996-12-03 NO NO965160A patent/NO965160L/no unknown
- 1996-12-09 FI FI964920A patent/FI964920A7/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE175958T1 (de) | 1999-02-15 |
| TW365602B (en) | 1999-08-01 |
| FI964920A0 (fi) | 1996-12-09 |
| EP0764149A1 (fr) | 1997-03-26 |
| JPH10501259A (ja) | 1998-02-03 |
| AU2742195A (en) | 1996-01-05 |
| NO965160D0 (no) | 1996-12-03 |
| EP0764149B1 (fr) | 1999-01-20 |
| FI964920A7 (fi) | 1996-12-09 |
| WO1995034535A1 (fr) | 1995-12-21 |
| PL317580A1 (en) | 1997-04-14 |
| CN1150419A (zh) | 1997-05-21 |
| CA2192389A1 (fr) | 1995-12-21 |
| SK158196A3 (en) | 1997-07-09 |
| NO965160L (no) | 1996-12-03 |
| DE69507476D1 (de) | 1999-03-04 |
| CZ361996A3 (en) | 1997-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9508187A (pt) | Produtos e composição farmacêutica | |
| NO973222L (no) | Nye farnesyl-transferase-inhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende inhibitorene | |
| WO2004071388A3 (en) | Medicinal compounds | |
| CA2304713A1 (en) | Biphenyl-5-alkanoic acid derivatives and use thereof | |
| FI972366A0 (fi) | Lipopolyamiinit transfektoivina aineina ja niiden farmaseuttinen käyttö | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| DE69415445D1 (de) | Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| MX9707561A (es) | Compuestos de carbonil piperazinilo y piperidinilo. | |
| ES2137169T3 (es) | Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene. | |
| ES2076009T3 (es) | Nuevos inhibidores de n-miristoil-transferasa, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| ES8200011A1 (es) | Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa. | |
| ES2145003T3 (es) | Composicion que contiene un derivado de dioxabiciclo(3.3.0)octano. | |
| GR3001879T3 (en) | Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them | |
| NZ505614A (en) | Pentasaccharides and pharmaceutical compositions thereof, useful as anti blood clotting agnets | |
| CA2127067A1 (fr) | Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| IL95762A0 (en) | Benzanilides,their preparation and pharmaceutical compositions containing the same | |
| BR9604907B1 (pt) | derivados de nucleosidios homocarbociclico de pirimidinodiona substituìda antiviral e composição contendo derivados de nucleosidios homocarbociclico de pirimidinodiona substituìda antiviral com princìpios ativos. | |
| MX9606106A (es) | Nuevos inhibidores de farnesil-trasnferasa, su preparacion y las composiciones farmaceuticas que los contienen. | |
| FI932641A0 (fi) | Nytt estradiolderivat-klorambucil-konjugat, foerfarande foer dess framstaellning och farmaceutiska kompositioner | |
| SE9701912D0 (sv) | Pharmaceutical composition and use thereof | |
| DE60119383D1 (de) | Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate | |
| DE3563048D1 (en) | 2-pyridine-thiol derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| DE69822167D1 (de) | Antimikrobielle verbindungen | |
| MX9802679A (es) | Derivados de ditiolan, su preparacion y su efecto terapeutico. | |
| KR950000638A (ko) | 3, 4-디히드록시칼콘 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
| FA14 | Dismissal: dismissal - article 34 of industrial property law | ||
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: REFERENTE A RPI DE 20030506 |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |